Halia Therapeutics Participates in Biotech Forum

LEHI, Utah, Oct. 7, 2026 /CourierPR/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class therapies targeting inflammasome-driven disease biology, has announced its participation in the 6th Annual Needham Private Biotech & MedTech Company Virtual 1x1 Forum, scheduled to take place on October 13-14, 2026.

Halia Therapeutics, headquartered in Lehi, Utah, is dedicated to addressing significant unmet needs in hematologic diseases through the development of novel therapies. The company's lead program, ofirnoflast, is being developed for lower-risk Myelodysplastic Syndromes (MDS) and other hematologic diseases driven by NLRP3 inflammasome biology. Its broader pipeline is grounded in human genetic resilience and precision medicine.

The company's participation in the Needham Private Biotech & MedTech Company Virtual 1x1 Forum underscores its commitment to advancing its research and engaging with industry peers and investors. The forum, which is set to convene biotech and medtech companies, provides a platform for these companies to share their latest innovations and developments, fostering collaboration and knowledge exchange.

Halia Therapeutics is led by a team of experts in the field of biopharmaceuticals, who are dedicated to developing therapies that address critical unmet medical needs. The company's participation in the forum is expected to highlight its progress in the development of ofirnoflast and its broader pipeline, as well as its ongoing efforts to advance precision medicine in the treatment of hematologic diseases.

The forum, taking place on October 13-14, 2026, will provide Halia Therapeutics with an opportunity to engage with industry leaders and investors, furthering its mission to develop innovative therapies that improve the lives of patients suffering from hematologic diseases.